Loading...

Amedisys

Nasdaq:AMED
Snowflake Description

Outstanding track record with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AMED
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
AMED Share Price and Events
7 Day Returns
2.9%
NasdaqGS:AMED
0.8%
US Healthcare
1.2%
US Market
1 Year Returns
38.4%
NasdaqGS:AMED
-2.8%
US Healthcare
2.3%
US Market
AMED Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Amedisys (AMED) 2.9% 11.2% -3.9% 38.4% 146.2% 806.8%
US Healthcare 0.8% 3.5% -0.9% -2.8% 23.6% 63.1%
US Market 1.2% 2% 2% 2.3% 37.9% 39.8%
1 Year Return vs Industry and Market
  • AMED outperformed the Healthcare industry which returned -2.8% over the past year.
  • AMED outperformed the Market in United States of America which returned 2.3% over the past year.
Price Volatility
AMED
Industry
5yr Volatility vs Market

AMED Value

 Is Amedisys undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Amedisys to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Amedisys.

NasdaqGS:AMED Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:AMED
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.639 (1 + (1- 21%) (10.05%))
0.792
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqGS:AMED using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Amedisys is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:AMED DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 158.73 Analyst x2 147.66
2020 182.57 Analyst x3 157.99
2021 200.99 Est @ 10.09% 161.80
2022 216.84 Est @ 7.88% 162.38
2023 230.58 Est @ 6.34% 160.63
2024 242.70 Est @ 5.26% 157.28
2025 253.61 Est @ 4.5% 152.89
2026 263.68 Est @ 3.97% 147.87
2027 273.16 Est @ 3.6% 142.50
2028 282.27 Est @ 3.34% 136.98
Present value of next 10 years cash flows $1,527.97
NasdaqGS:AMED DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $282.27 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$6,081.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,081.75 ÷ (1 + 7.5%)10
$2,951.38
NasdaqGS:AMED Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,527.97 + $2,951.38
$4,479.35
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,479.35 / 32.04
$139.78
NasdaqGS:AMED Discount to Share Price
Calculation Result
Value per share (USD) From above. $139.78
Current discount Discount to share price of $121.42
= -1 x ($121.42 - $139.78) / $139.78
13.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Amedisys is available for.
Intrinsic value
13%
Share price is $121.42 vs Future cash flow value of $139.78
Current Discount Checks
For Amedisys to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Amedisys's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Amedisys's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Amedisys's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Amedisys's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:AMED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $3.82
NasdaqGS:AMED Share Price ** NasdaqGS (2019-06-19) in USD $121.42
United States of America Healthcare Industry PE Ratio Median Figure of 57 Publicly-Listed Healthcare Companies 20.87x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Amedisys.

NasdaqGS:AMED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AMED Share Price ÷ EPS (both in USD)

= 121.42 ÷ 3.82

31.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amedisys is overvalued based on earnings compared to the US Healthcare industry average.
  • Amedisys is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Amedisys's expected growth come at a high price?
Raw Data
NasdaqGS:AMED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 31.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
15.8%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 43 Publicly-Listed Healthcare Companies 1.65x
United States of America Market PEG Ratio Median Figure of 2,128 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

NasdaqGS:AMED PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 31.76x ÷ 15.8%

2.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amedisys is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Amedisys's assets?
Raw Data
NasdaqGS:AMED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $16.24
NasdaqGS:AMED Share Price * NasdaqGS (2019-06-19) in USD $121.42
United States of America Healthcare Industry PB Ratio Median Figure of 93 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,246 Publicly-Listed Companies 1.8x
NasdaqGS:AMED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AMED Share Price ÷ Book Value per Share (both in USD)

= 121.42 ÷ 16.24

7.48x

* Primary Listing of Amedisys.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amedisys is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Amedisys's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Amedisys has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AMED Future Performance

 How is Amedisys expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Amedisys expected to grow at an attractive rate?
  • Amedisys's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Amedisys's earnings growth is expected to exceed the United States of America market average.
  • Amedisys's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:AMED Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:AMED Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 15.8%
NasdaqGS:AMED Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 7.9%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:AMED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:AMED Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,277 189 1
2020-12-31 2,101 192 152 11
2019-12-31 1,966 133 130 11
NasdaqGS:AMED Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1,731 203 123
2018-12-31 1,663 223 119
2018-09-30 1,624 192 88
2018-06-30 1,580 133 71
2018-03-31 1,546 119 42
2017-12-31 1,511 106 30
2017-09-30 1,474 102 43
2017-06-30 1,456 99 40
2017-03-31 1,438 77 46
2016-12-31 1,419 62 37
2016-09-30 1,391 54 41
2016-06-30 1,358 78 38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Amedisys's earnings are expected to grow by 15.8% yearly, however this is not considered high growth (20% yearly).
  • Amedisys's revenue is expected to grow by 7.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:AMED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Amedisys Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMED Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 5.57 5.57 5.57 1.00
2020-12-31 4.55 4.75 4.39 7.00
2019-12-31 3.93 3.94 3.91 7.00
NasdaqGS:AMED Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 3.82
2018-12-31 3.64
2018-09-30 2.65
2018-06-30 2.11
2018-03-31 1.25
2017-12-31 0.90
2017-09-30 1.28
2017-06-30 1.19
2017-03-31 1.39
2016-12-31 1.12
2016-09-30 1.24
2016-06-30 1.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Amedisys is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Amedisys's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Amedisys has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AMED Past Performance

  How has Amedisys performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Amedisys's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Amedisys has delivered over 20% year on year earnings growth in the past 5 years.
  • Amedisys's 1-year earnings growth exceeds its 5-year average (191.7% vs 67.9%)
  • Amedisys's earnings growth has exceeded the US Healthcare industry average in the past year (191.7% vs 2.2%).
Earnings and Revenue History
Amedisys's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Amedisys Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMED Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1,730.66 123.49 524.80
2018-12-31 1,662.58 119.35 501.31
2018-09-30 1,623.51 88.04 492.06
2018-06-30 1,579.88 71.22 484.39
2018-03-31 1,545.87 42.33 482.22
2017-12-31 1,511.27 30.30 479.61
2017-09-30 1,473.75 43.07 481.39
2017-06-30 1,456.17 39.94 488.94
2017-03-31 1,437.72 46.18 494.68
2016-12-31 1,419.26 37.26 503.43
2016-09-30 1,391.18 41.26 498.85
2016-06-30 1,357.87 38.26 487.03
2016-03-31 1,312.77 38.20 475.93
2015-12-31 1,266.49 -3.02 452.44
2015-09-30 1,230.36 -6.80 437.34
2015-06-30 1,203.64 -6.80 427.01
2015-03-31 1,193.01 -9.88 419.45
2014-12-31 1,188.26 12.99 432.74
2014-09-30 1,190.76 -4.31 441.12
2014-06-30 1,192.00 -103.09 454.71
2014-03-31 1,202.56 -108.65 464.33
2013-12-31 1,233.46 -93.11 470.77
2013-09-30 1,278.35 -190.88 486.11
2013-06-30 1,339.87 -90.18 497.00
2013-03-31 1,394.27 -83.67 512.04
2012-12-31 1,419.83 -80.26 516.67
2012-09-30 1,441.38 33.11 520.16
2012-06-30 1,448.46 -399.49 528.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Amedisys has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Amedisys used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
  • Amedisys has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Amedisys's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Amedisys has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AMED Health

 How is Amedisys's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Amedisys's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Amedisys's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Amedisys's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Amedisys's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Amedisys Company Filings, last reported 2 months ago.

NasdaqGS:AMED Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 521.20 391.13 10.55
2018-12-31 482.63 7.39 20.23
2018-09-30 445.50 56.06 14.01
2018-06-30 409.06 124.61 25.90
2018-03-31 549.56 86.20 120.01
2017-12-31 516.43 88.84 86.36
2017-09-30 513.22 89.91 66.11
2017-06-30 493.06 91.29 59.16
2017-03-31 482.95 92.36 48.33
2016-12-31 461.14 93.03 30.20
2016-09-30 446.38 94.09 8.92
2016-06-30 427.83 94.50 9.97
2016-03-31 410.78 110.57 7.82
2015-12-31 410.44 96.63 27.50
2015-09-30 393.97 100.00 57.05
2015-06-30 380.05 95.52 33.20
2015-03-31 367.44 98.44 3.13
2014-12-31 397.76 116.37 8.03
2014-09-30 383.10 114.30 5.54
2014-06-30 371.04 144.28 11.23
2014-03-31 362.92 42.95 2.84
2013-12-31 372.48 46.90 17.30
2013-09-30 377.79 70.86 43.63
2013-06-30 465.03 74.81 30.12
2013-03-31 461.78 78.76 7.02
2012-12-31 454.23 102.71 14.55
2012-09-30 571.98 122.16 39.11
2012-06-30 541.32 128.40 37.16
  • Amedisys's level of debt (59.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (12.1% vs 59.4% today).
  • Debt is well covered by operating cash flow (65.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 18.5x coverage).
X
Financial health checks
We assess Amedisys's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Amedisys has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AMED Dividends

 What is Amedisys's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Amedisys dividends. Estimated to be 0% next year.
If you bought $2,000 of Amedisys shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Amedisys's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Amedisys's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:AMED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:AMED Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Amedisys has not reported any payouts.
  • Unable to verify if Amedisys's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Amedisys's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Amedisys has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Amedisys's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Amedisys's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Amedisys afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Amedisys has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AMED Management

 What is the CEO of Amedisys's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Kusserow
COMPENSATION $4,866,439
AGE 57
TENURE AS CEO 4.5 years
CEO Bio

Mr. Paul Berthold Kusserow has been the Chief Executive Officer and President of Amedisys, Inc. since December 16, 2014. He serves as Chairman of the Advisory Board of Care Innovations. He has been the Chairman of the Board of Availity, LLC. since May 2013. He serves as member of the advisory board of Interpreta. He has been a Director of Community Care Health Network, Inc. since May 30, 2017. He has been a Director of Amedisys, Inc. since December 16, 2014. He serves as Director of Picwell Inc., New Century Health, Inc. and AxelaCare Health Solutions, LLC. He serves as a Director of IdealHire Technologies, Inc. Mr. Kusserow served as the President, Development of Alignment Healthcare, Inc. from June 2014 to December 2014. He served as the Chief Strategy, Innovations and Corporate Development Officer and Senior Vice President at Humana Inc. from January 2008 through December 2013. He served as the Chief Strategy Officer and Senior Vice President at Humana Venture Capital. He served as Managing Director and Chief Investment Officer at Ziegler HealthVest Fund at Contemporary Healthcare Capital, LLC. He served as a Managing Partner at Roaring Mountain, LLC and as an Entrepreneur-In-Residence at DW Healthcare Partners. He was the Managing Director of Private Equity at B.C. Ziegler and Company, Inc. He served as Executive-In-Residence of The Advisory Board Company. Previously, he co-founded San Ysidro Capital Partners LLC and served as its Managing Director from 2004 to 2007. From 1997 to 2004, he served as Tenet Healthcare Corporation's Senior Vice President of Corporate Strategy and Ventures, where he managed its venture investments and founded Tenet Ventures. He started his career as a Consultant with McKinsey & Company, Inc., where he specialized in marketing and organizational redesign. He has deep experience, especially in growing companies and corporate development. He previously served as the chairman of the board of directors of Availity Inc. and Healthsense, Inc. He served as Vice Chairman at Alignment Healthcare, Inc. since June 2014. He served as an Independent Director of Connecture, Inc. from October 2014 to April 25, 2018. He served as a Director of Actors Theatre of Louisville, Inc. He served as the Head of Planning and Marketing at the Colonial Williamsburg Foundation, where he was responsible for strategic planning, new business development and marketing. Mr. Kusserow also served senior executive positions in marketing, strategy and new business development at the National Geographic Society and the Reader's Digest Association. He was a Philip B. Brown Scholar, a Trench Prize recipient, an Olin Fellow and a Fellow at the Center for the Humanities at Wesleyan University. He received an M.A. degree, with honors, in English literature from the Oxford University. Mr. Kusserow graduated in BA in religious studies from the Wesleyan University.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Paul's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Amedisys management team in years:

2.6
Average Tenure
53
Average Age
  • The tenure for the Amedisys management team is about average.
Management Team

Paul Kusserow

TITLE
President
COMPENSATION
$5M
AGE
57
TENURE
4.5 yrs

Scott Ginn

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
49
TENURE
1.7 yrs

Chris Gerard

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
51
TENURE
2.4 yrs

Dave Kemmerly

TITLE
Senior VP of Government Affairs & General Counsel
COMPENSATION
$1M
AGE
55
TENURE
3.7 yrs

Sharon Brunecz

TITLE
Chief Human Resources Officer
COMPENSATION
$2M
AGE
51
TENURE
1.1 yrs

Pete Hartley

TITLE
CTO & Senior VP of Business Operations Systems

Michael North

TITLE
Chief Information Officer
COMPENSATION
$1M
AGE
53
TENURE
2.6 yrs

David Pearce

TITLE
SVP & Chief Compliance Officer
AGE
57
TENURE
2.9 yrs

Kendra Kimmons

TITLE
Vice President of Marketing & Communications

John Nugent

TITLE
Chief Acquisitions Officer
Board of Directors Tenure

Average tenure and age of the Amedisys board of directors in years:

4.5
Average Tenure
62
Average Age
  • The tenure for the Amedisys board of directors is about average.
Board of Directors

Don Washburn

TITLE
Non-Executive Chairman
COMPENSATION
$209K
AGE
74
TENURE
4.8 yrs

Paul Kusserow

TITLE
President
COMPENSATION
$5M
AGE
57
TENURE
4.5 yrs

Jake Netterville

TITLE
Director
COMPENSATION
$134K
AGE
80
TENURE
22.4 yrs

Linda J. Keller

TITLE
Director
COMPENSATION
$121K
AGE
69
TENURE
6.3 yrs

Julie Klapstein

TITLE
Director
COMPENSATION
$122K
AGE
63
TENURE
3.2 yrs

Rich Lechleiter

TITLE
Director
COMPENSATION
$125K
AGE
60
TENURE
3.2 yrs

Nat Zilkha

TITLE
Director
COMPENSATION
$114K
AGE
42
TENURE
5.3 yrs

Bruce Perkins

TITLE
Director
COMPENSATION
$122K
AGE
62
TENURE
4.2 yrs

Jeff Rideout

TITLE
Director
COMPENSATION
$105K
AGE
56
TENURE
3.2 yrs
Who owns this company?
Recent Insider Trading
  • Amedisys insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Jun 19 Sell Jake Netterville Individual 13. Jun 19 13. Jun 19 -1,863 $118.17 $-220,151
13. Jun 19 Sell Scott Ginn Individual 10. Jun 19 10. Jun 19 -4,872 $118.50 $-577,332
07. Jun 19 Sell Michael North Individual 05. Jun 19 05. Jun 19 -5,248 $115.01 $-603,572
07. Jun 19 Sell David Kemmerly Individual 06. Jun 19 06. Jun 19 -4,420 $113.40 $-501,228
18. May 19 Buy Bruce Perkins Individual 15. May 19 15. May 19 2,500 $111.84 $279,597
13. Mar 19 Sell David Pearce Individual 12. Mar 19 12. Mar 19 -4,370 $120.01 $-524,444
13. Mar 19 Sell Christopher Gerard Individual 11. Mar 19 11. Mar 19 -2,500 $118.96 $-297,400
07. Mar 19 Sell Jeffrey Rideout Individual 04. Mar 19 04. Mar 19 -1,411 $122.69 $-171,549
10. Jan 19 Sell Linda J. Keller Individual 09. Nov 18 09. Nov 18 -5,256 $120.00 $-630,720
20. Nov 18 Sell Jake Netterville Individual 15. Nov 18 16. Nov 18 -3,394 $126.64 $-416,984
15. Nov 18 Sell Scott Ginn Individual 12. Nov 18 12. Nov 18 -2,015 $119.01 $-238,566
X
Management checks
We assess Amedisys's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Amedisys has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AMED News

Simply Wall St News

A Close Look At Amedisys, Inc.’s (NASDAQ:AMED) 18% ROCE

The formula for calculating the return on capital employed is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Amedisys: 0.18 = US$163m ÷ (US$1.2b - US$297m) (Based on the trailing twelve months to March 2019.) So, Amedisys has an ROCE of 18%. … Amedisys's Current Liabilities And Their Impact On Its ROCE Current liabilities include invoices, such as supplier payments, short-term debt, or a tax bill, that need to be paid within 12 months. … The ROCE equation subtracts current liabilities from capital employed, so a company with a lot of current liabilities appears to have less capital employed, and a higher ROCE than otherwise.

Simply Wall St -

Is It Too Late To Consider Buying Amedisys, Inc. (NASDAQ:AMED)?

And if you believe the company’s true value is $134.74, then there isn’t much room for the share price grow beyond what it’s currently trading. … AMED’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. … Will you have enough confidence to invest in the company should the price drop below its fair value?

Simply Wall St -

What You Should Know About Amedisys, Inc.'s (NASDAQ:AMED) Financial Strength

Does AMED Produce Much Cash Relative To Its Debt? … Additionally, AMED has produced US$203m in operating cash flow over the same time period, leading to an operating cash to total debt ratio of 52%, meaning that AMED’s operating cash is sufficient to cover its debt. … Looking at AMED’s US$297m in current liabilities, it seems that the business may not have an easy time meeting these commitments with a current assets level of US$272m, leading to a current ratio of 0.91x.

Simply Wall St -

Here's Why I Think Amedisys (NASDAQ:AMED) Might Deserve Your Attention Today

So it is good to see that Amedisys insiders have a significant amount of capital invested in the stock. … Although Amedisys certainly looks good to me, I would like it more if insiders were buying up shares. … If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Simply Wall St -

Investors Who Bought Amedisys (NASDAQ:AMED) Shares Five Years Ago Are Now Up 676%

There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During the five years of share price growth, Amedisys moved from a loss to profitability. … This EPS growth is higher than the 33% average annual increase in the share price over the same three years.

Simply Wall St -

Is Amedisys, Inc.'s (NASDAQ:AMED) Stock Available For A Good Price After Accounting For Growth?

Looking at Amedisys, Inc.’s (NASDAQ:AMED) fundamentals some investors are wondering if its last closing price of $127.88 represents a good value for money for this high growth stock. … See our latest analysis for Amedisys? … According to the analysts covering the company, the following few years should bring about good growth prospects for Amedisys

Simply Wall St -

What Are Analysts Saying About Amedisys, Inc.'s (NASDAQ:AMED) Future?

After Amedisys, Inc.'s (NASDAQ:AMED) earnings announcement in December 2018,. … with earnings expected to grow by 12% in the upcoming year … the higher past 5-year average growth rate of 71%

Simply Wall St -

Calculating The Intrinsic Value Of Amedisys, Inc. (NASDAQ:AMED)

Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model? … We're using the 2-stage growth model, which simply means we take in account two stages of company's growth … In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate.

Simply Wall St -

Boasting A 25% Return On Equity, Is Amedisys, Inc. (NASDAQ:AMED) A Top Quality Stock?

This article is for those who would like to learn about Return On Equity (ROE). … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.25. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Are Insiders Selling Amedisys, Inc. (NASDAQ:AMED) Stock?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So shareholders might well want to know whether insiders have been buying or selling shares in Amedisys, Inc. … Over the last year we saw more insider selling of Amedisys shares, than buying

Simply Wall St -

AMED Company Info

Description

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer’s, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Details
Name: Amedisys, Inc.
AMED
Exchange: NasdaqGS
Founded: 1982
$3,890,725,219
32,044,848
Website: http://www.amedisys.com
Address: Amedisys, Inc.
3854 American Way,
Suite A,
Baton Rouge,
Louisiana, 70816,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AMED Common Stock Nasdaq Global Select US USD 06. Jan 1994
DB ADY Common Stock Deutsche Boerse AG DE EUR 06. Jan 1994
BMV AMED * Common Stock Bolsa Mexicana de Valores MX MXN 06. Jan 1994
Number of employees
Current staff
Staff numbers
21,000
Amedisys employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 23:32
End of day share price update: 2019/06/19 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.